Astrazeneca (AZN) Non-Current Assets (2009 - 2026)
Astrazeneca (AZN) posted quarterly Non-Current Assets of $87.9 billion for Q2 2026, up 5.25% year-over-year from $83.5 billion in Q2 2025, and up 4.11% quarter-over-quarter from $84.4 billion in Q1 2026.
Astrazeneca (AZN) Non-Current Assets (2009 - 2026) Analysis & Trends
Astrazeneca's Non-Current Assets history runs 18 years deep, the most recent figure standing at $87.9 billion for Q2 2026.
- In Q2 2026, Non-Current Assets rose 5.25% year-over-year to $87.9 billion; the TTM figure through Mar 2026 stood at $84.4 billion (up 5.35% YoY), while the FY2025 annual figure was $85.4 billion, up 21.47% from the prior year.
- Non-Current Assets for Q2 2026 stood at $87.9 billion, up from $84.4 billion in the prior quarter.
- The five-year high for Non-Current Assets was $87.9 billion in Q2 2026, with the low at $68.9 billion in Q4 2022.
- The 5-year median for Non-Current Assets is $77.2 billion (2022), against an average of $77.7 billion.
- Peak annual rise in Non-Current Assets reached 112.7% in 2022, while the deepest fall reached 8.16% in 2022.
- Astrazeneca's Non-Current Assets stood at $68.9 billion in 2022, then grew by 0.15% to $69.0 billion in 2023, then rose by 1.88% to $70.3 billion in 2024, then climbed by 21.47% to $85.4 billion in 2025, then grew by 2.95% to $87.9 billion in 2026.
- Business Quant data shows AZN's Non-Current Assets at $87.9 billion in Q2 2026, $84.4 billion in Q1 2026, and $85.4 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 141.29 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 101.45 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 125.00 Mn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 94.68 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 87.87 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 60.68 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 35.42 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 159.77 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 59.27 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 113.37 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 87.87 Bn |
| Mar 31, 2026 | 84.40 Bn |
| Dec 31, 2025 | 85.35 Bn |
| Sep 30, 2025 | 84.52 Bn |
| Jun 30, 2025 | 83.48 Bn |
| Mar 31, 2025 | 80.11 Bn |
| Dec 31, 2024 | 70.26 Bn |
| Sep 30, 2024 | 80.77 Bn |
| Jun 30, 2024 | 78.95 Bn |
| Mar 31, 2024 | 76.70 Bn |
| Dec 31, 2023 | 68.97 Bn |
| Sep 30, 2023 | 73.59 Bn |
| Jun 30, 2023 | 73.70 Bn |
| Mar 31, 2023 | 74.42 Bn |
| Dec 31, 2022 | 68.86 Bn |
| Sep 30, 2022 | 73.96 Bn |
| Jun 30, 2022 | 75.66 Bn |
| Mar 31, 2022 | 77.63 Bn |
| Dec 31, 2021 | 73.01 Bn |
| Sep 30, 2021 | 80.53 Bn |